S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL)|
|Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology|
|Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II Trial in HER2 Positive Metastatic Breast Cancer (NEfERTT Trial)|
|IMBRUVICA® (ibrutinib) Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients|
|BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium|
|OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to Bevacizumab Significantly Increases Progression-Free Survival in Recurrent Ovarian Cancer|
|Merck Announces Positive Study Investigating the Use of KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma|
|Cerulean Reports Third-Quarter 2014 Corporate Highlights and Financial Results|
|IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy (2014/12/9)|
|IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy (2014/12/8)|
Click above to view more mutual fund data and stats for orr - China Power New Energy Development Co Ltd.